Regorafenib is a multi-kinase inhibitor in use for the treatment of colorectal cancer (CRC). To improve drug pharmacokinetics and bioavailability, here the authors design mannose-modified cyclodextrin-based host-guest complexes loaded with Regorafenib, showing anti-tumor responses in preclinical models of CRC.
- Hongzhen Bai
- Jianwei Wang
- Guping Tang
